- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Los Altos Today
By the People, for the People
Noble Financial Boosts Forecast for Unicycive Therapeutics Q1 Earnings
Analysts raise estimates for the biotech firm's first-quarter results.
Apr. 2, 2026 at 11:36am
Got story updates? Submit your updates here. ›
Equities research analysts at Noble Financial have increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY). Noble Financial analyst R. Leboyer now anticipates the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.47).
Why it matters
This positive forecast from a respected financial research firm suggests Unicycive Therapeutics may be performing better than expected in the first quarter, which could signal improving financial health and growth prospects for the biotech company.
The details
Noble Financial also issued estimates for Unicycive Therapeutics' Q2 2026 earnings at ($0.52) EPS, Q4 2026 earnings at $0.87 EPS and FY2026 earnings at $0.85 EPS. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share.
- Noble Financial issued the updated Q1 2026 EPS forecast on Tuesday, March 31st.
The players
Noble Financial
An equities research firm that covers Unicycive Therapeutics.
R. Leboyer
A Noble Financial analyst who covers Unicycive Therapeutics.
Unicycive Therapeutics, Inc.
A biotechnology company developing novel therapies for kidney diseases.
What they’re saying
“Noble Financial analyst R. Leboyer now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.47).”
— R. Leboyer, Analyst
What’s next
Investors will be watching closely to see if Unicycive Therapeutics can meet or exceed Noble Financial's updated Q1 2026 earnings forecast when the company reports its results.
The takeaway
This positive earnings revision from a respected research firm suggests Unicycive Therapeutics may be making progress in developing its pipeline of kidney disease treatments, which could bode well for the company's future financial performance.
